Posts by Clarion

Key Lessons for Future Cell & Gene Therapies


By Heather Drexler, Anna May Fitch, Caleb Rhodes, Carolyn Zheng, Olivia Okoli, Seth Henks, Ellen Edenberg, and Bobby Moy The first cell and gene therapy products have launched, but the development pipeline suggests a potential explosion in the space moving forward with hundreds of assets in clinical and preclinical development across a variety of platforms…

Read More

Keytruda approval for TMB-high tumors: A double-edged sword?


By Martin Strebl-Bantillo and Dennis Chang Immune checkpoint inhibitors (ICIs)—including anti-CTLA4, anti-PD1, and anti-PD-L1 antibodies—have transformed the landscape of cancer treatment, reshaped standards of care, and for some patients cured their disease. To date, the FDA has approved 7 ICI agents1 that together drove more than 24 billion USD in global sales in 20192. At…

Read More

Is Clarion the right place to advance your career?

Find out more about joining Clarion’s team of innovation advisors.

A life sciences strategy and organizational consultancy that collaborates with its clients to envision, craft and enable growth through innovation and leadership.